Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | BCR | P11274 | 1/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21456907 | 0.89 | ABL1 (0.79) | ABL1KCNH2BCRCRBN | |
| SCHEMBL21456905 | 0.89 | ABL1 (0.79) | ABL1KCNH2BCRCRBN | |
| SCHEMBL21456916 | 0.88 | ABL1 (0.81) | ABL1KCNH2BCRCRBN | |
| SCHEMBL23522293 | 0.88 | ABL1 (0.81) | ABL1KCNH2BCRCRBN | |
| SCHEMBL21456914 | 0.88 | ABL1 (0.81) | ABL1KCNH2BCRCRBN | |
| SCHEMBL21477576 | 0.87 | ABL1 (0.80) | ABL1KCNH2BCRCRBN | |
| SCHEMBL22711587 | 0.87 | ABL1 (0.80) | ABL1KCNH2BCRCRBN | |
| SCHEMBL16860476 | 0.86 | ABL1 (1.00) | ABL1KCNH2BCRCRBN | |
| SCHEMBL16860474 | 0.86 | ABL1 (1.00) | ABL1KCNH2BCRCRBN | |
| SCHEMBL21456913 | 0.86 | ABL1 (0.80) | ABL1KCNH2BCRCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| EP-3838897-A2 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3838897-A2 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2021-06-23 | — | — | EP | disclosed |
| EP-3553056-B1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2021-02-17 | — | — | EP | disclosed |
| EP-3553056-B1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| EP-3553056-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-10-16 | — | — | EP | disclosed |
| EP-3553056-A1 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | ABL1 45/4885KCNH2 946/4885BCR 941/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | ABL1 40/4885KCNH2 974/4885BCR 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.